Reaction
Anaplastic Large Cell Lymphoma T- And Null-Cell Types Recurrent reporting signals
As of the last recalculation, Anaplastic Large Cell Lymphoma T- And Null-Cell Types Recurrent appears in 28 FAERS reports alongside 2 co-occurring drug terms. The strongest observed disproportionality signal is BRENTUXIMAB VEDOTIN (PRR 2,341.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Brentuximab Vedotin | 15 | 2,341.9 | 2,345.4 |
| Crizotinib | 3 | 196.4 | 196.4 |